Evidence map›Paper›PMID 36941908›Full record

ReviewClinical pharmacology : advances and applications2023

Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults.

Wubetu Yihunie, Bekalu Kebede, Bantayehu Addis Tegegne, Melese Getachew, Dehnnet Abebe, Yibeltal Aschale, Habtamu Belew, Bereket Bahiru

Open access · goldAbstract readReview
In one paragraph

Review in Clinical pharmacology : advances and applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Leaf Saponins ofPharmaceutics · 2025
    Review
  2. Review
  3. The recent advances in vaccine adjuvants.Frontiers in immunology · 2025
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wubetu YihunieDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0003-2703-8941
Bekalu KebedeDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Bantayehu Addis TegegneDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0002-6178-8335
Melese GetachewDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0003-3397-0022
Dehnnet AbebeDepartment of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0002-7004-1735
Yibeltal AschaleDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Habtamu BelewDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.ORCID 0000-0003-0401-0890
Bereket BahiruDepartment of Pharmacy, College of Medicine and health sciences, Bahir Dar University, Bahir Dar, Ethiopia.ORCID 0000-0002-1758-348X
Debre Markos University · ETBahir Dar University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Emergence of antimalarial drugs and insecticides resistance alarms scientists to develop a safe and effective malaria vaccine. A pre-erythrocytic malaria vaccine called RTS,S has made great strides. Aim: The review was aimed to assess the safety of the candidate malaria vaccine RTS,S with AS01 and AS02 adjuvants using data from Phase I-III randomized controlled clinical trials (RCTs). Methods: This systematic review was conducted based on PRISMA 2020. Regardless of time of publication year, all articles related with safety of RTS,S, RCTs published in the English language were included in the study. The last search of databases, and registry was conducted on 30 May, 2022. Pubmed, Google Scholar, Cochrane Library, Wiley Online Library, and Clinical trials.gov were thoroughly searched for accessible RCTs on the safety of RTS,S malaria vaccine. The studies were screened in three steps: duplicate removal, title and abstract screening, and full-text review. The included studies' bias risk was assessed using the Cochrane risk of bias tool for RCTs. This systematic review is registered at Prospero (registration number: CRD42021285888). The qualitative descriptive findings from the included published studies were reported stratified by clinical trial phases. Findings: A total of thirty-five eligible safety studies were identified. Injection site pain and swelling, febrile convulsion, fever, headache, meningitis, fatigue, gastroenteritis, myalgia, pneumonia, reactogenicity, and anemia were the most commonly reported adverse events. Despite few clinical trials reported serious adverse events, none of them were related to vaccination. Conclusion: Most of the adverse events observed from RTS,S/AS01 and RTS,S/AS02 malaria vaccines were reported in the control group and shared by other vaccines. Hence, the authors concluded that both RTS,S/AS01 and RTS,S/AS02 malaria vaccines are safe.

Indexed as

randomized controlled trialsRTS,S/AS01RTS,S/AS02safetysystematic review

Identifiers

PMID36941908
PMCPMC10024506
OpenAlexW4324145160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.